Kyverna Therapy Company
-
Business
Morgan Stanley says obscure autoimmune biotech stock could rise 40%
New public biotech Kyverna Therapeutics could be the developer of a blockbuster cell therapy for autoimmune disease, according to Morgan…
Read More »